… from participants were spiked ex vivo with apixaban 0 (APIX0), … the antiplatelet effects of
current antiplatelet treatments … of potential participants from consecutive patients admitted to the …

… and has two tyrosines in a conserved sequence known as an … vivo, alone and in combination
with apixaban, a factor Xa … , and ex vivo platelet-rich thrombus formation under conditions …

… Antithrombotic therapy plays a key role in the treatment of … a prospective, open-label,
parallel-group PD study enrolling 80 … Apixaban 2.5 mg twice daily and 10 mg once daily resulted …

… for thrombus formation and targets for oral antithrombotic … effects in in vitro assays and
enhances antithrombotic efficacy … • Apixaban added to standard antiplatelet therapy increased the …

… , making antithrombotic therapy challenging. Aim of this … and healthy controls by Next
Generation Sequencing. PC levels … 4x higher concentrations with Apixaban and Edoxaban than …

… randomized control studies assessing anticoagulation therapy and … Apixaban Recurrent
ischemic/hemorrhagic stroke Study in … A 2‐year study of 295 consecutive patients with ischemic …

… In vitro studies of platelet aggregation confirmed a … Dr Wael Sumaya kindly provided training
in fibrin clot turbidimetry. … coronary intervention and dual antiplatelet therapy. Some months …

… , namely Rivaroxaban, Apixaban and Edoxaban were … , controlled, open label clinical trial
aimed to investigate the … or PE allowed to stop oral anticoagulation treatment by their treating …

… would clearly benefit from antiplatelet therapy. However, … of SVD is the lack of in vivo models,
meaning that most of the … High-dose dabigatran and apixaban demonstrated superiority …

… of the HEART Trial sub-study population ...... 45 2.2.2 Dual antiplatelet therapy to Inhibit coronary
… Ex vivo validation of coronary artery specimens using 18F-fluoride demonstrated highly …